Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes
-
- Watanabe Noriko
- Departments of Pathology, Nihon University School of Medicine
-
- Nakanishi Yoko
- Departments of Pathology, Nihon University School of Medicine
-
- Kinukawa Noriko
- Departments of Pathology, Nihon University School of Medicine
-
- Ohni Sumie
- Departments of Pathology, Nihon University School of Medicine
-
- Obana Yukari
- Departments of Pathology, Nihon University School of Medicine
-
- Nakazawa Atsuko
- Department of Pathology, National Center for Child Health and Development
-
- Nemoto Norimichi
- Departments of Pathology, Nihon University School of Medicine
Search this article
Abstract
Somatostatin receptor (SSTR) expressions in neuroblastomas (NBs) have been confirmed employing various methods. High SSTR-2 expression was suggested to be a favorable prognostic marker, though little is known about the relationships between the expressions of SSTR subtypes, other than SSTR-2, and prognosis. We investigated the expressions of all five known SSTR subtypes in 63 neuroblastic tumors (NTs), employing immunohistochemistry, and also conducted quantitative real-time RT-PCR in 37 of these tumors. We evaluated correlations between the expressions of SSTR subtypes and prognosis, based on the International Neuroblastoma Pathology Classification and patient outcomes. More than 90% of cases expressed, at a minimum, SSTR-1 and/or 2. Ganglioneuromas and ganglioneuroblastomas expressed more than two SSTR subtypes. Among NBs, the favorable histology group showed higher SSTR subtype expressions than the unfavorable histology group. The same tendency was observed when surviving and deceased cases were compared, though SSTR-2 expression was well preserved in some of the deceased cases. In conclusion, NTs highly expressed SSTR-1 and/or 2, and expressions of SSTR generally indicate a good prognosis. However, even those in the unfavorable histology group with NBs expressing SSTR are good candidates for molecular targeting therapy using somatostatin analogues.
Journal
-
- ACTA HISTOCHEMICA ET CYTOCHEMICA
-
ACTA HISTOCHEMICA ET CYTOCHEMICA 47 (5), 219-229, 2014
JAPAN SOCIETY OF HISTOCHEMISTRY AND CYTOCHEMISTRY
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679839216128
-
- NII Article ID
- 130004687245
-
- ISSN
- 13475800
- 00445991
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed